Eli Lilly agreed to license rights from CSL Limited for clazakizumab, an IL‑6‑targeting monoclonal antibody, paying an initial $100 million with additional clinical, regulatory and commercial milestones possible. Under the pact CSL retains development rights for clazakizumab in end‑stage kidney disease while Lilly gains rights to pursue other indications where IL‑6 blockade could compete with established players. Lilly framed the transaction as a strategic addition to its inflammation/immunology pipeline amid strong cash flow from its metabolic franchise. Analysts noted the deal broadens Lilly’s exposure to IL‑6 biology and positions the company to test the antibody in indications beyond those CSL pursues. The agreement also underscores continued M&A and licensing activity by large pharma to supplement internal R&D.